University Of Nottingham hosts Lewis Capaldi
Lewis Capaldi, who recently revealed that he has Tourette syndrome, visited the Neupulse research team at the University of Nottingham, to try out a revolutionary new wearable device that is aimed at reducing tics in those with Tourette syndrome.
This Neupulse device, based on research conducted at the University of Nottingham, is now being developed by a University spin-out company, Neurotherapeutics Ltd, to help the millions of people worldwide who live with Tourette syndrome and tic disorders. The Neupulse device is a wrist-mounted, watch-like, device that delivers mild trains of electrical stimulation directly to the nerves in the wrist and influences the brain networks involved in generating tics.
During his visit, Lewis was eager to try out the Neupulse device for himself to see if it could reduce his tics. Professor Stephen Jackson who has led the research at the University of Nottingham said: “The results were remarkable – Lewis stated that the stimulation made him feel calmer and the device clearly suppressed the head and shoulder tics which can be quite painful for him.
“Though the Neupulse device is still early in development, the preliminary results of our UK-wide double-blind clinical trial have been extremely encouraging. This device has the potential to dramatically improve the lives of those with Tourette syndrome, who often face challenges managing their tics, by providing increased control over their tics on demand.”
Lewis reported that he was impressed by the effects of the device and is eager to try it out again in the future. Stephen added: “He was also very kind to the research team, taking the time for selfies and photographs with the team. He also very generously invited the whole team to his Friday night concert in Nottingham.”
The Neupulse device has the potential to be a game-changer for individuals with Tourette syndrome, and the world is eager to see the results of the clinical trial that will be published later this year. With its innovative technology and promising early results, the Neupulse device is poised to make a significant impact on the lives of those with Tourette’s syndrome.